WO2007067681A3 - Compositions et méthodes immunostimulatoires - Google Patents

Compositions et méthodes immunostimulatoires Download PDF

Info

Publication number
WO2007067681A3
WO2007067681A3 PCT/US2006/046662 US2006046662W WO2007067681A3 WO 2007067681 A3 WO2007067681 A3 WO 2007067681A3 US 2006046662 W US2006046662 W US 2006046662W WO 2007067681 A3 WO2007067681 A3 WO 2007067681A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
provides
immune
antigen
useful
Prior art date
Application number
PCT/US2006/046662
Other languages
English (en)
Other versions
WO2007067681A2 (fr
Inventor
Haval Shirwan
Kutlu G Elpek
Esma S Yolcu
Original Assignee
Univ Louisville Res Found
Haval Shirwan
Kutlu G Elpek
Esma S Yolcu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Louisville Res Found, Haval Shirwan, Kutlu G Elpek, Esma S Yolcu filed Critical Univ Louisville Res Found
Priority to AU2006321888A priority Critical patent/AU2006321888A1/en
Priority to JP2008544500A priority patent/JP5564181B2/ja
Priority to CA2632663A priority patent/CA2632663C/fr
Priority to MX2008007292A priority patent/MX2008007292A/es
Priority to EP06848503A priority patent/EP1976565A2/fr
Publication of WO2007067681A2 publication Critical patent/WO2007067681A2/fr
Publication of WO2007067681A3 publication Critical patent/WO2007067681A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

L'invention concerne des conjugués comprenant un polypeptide co-stimulatoire immun et un antigène ou un agent infectieux. Les conjugués sont utiles pour la génération ou l'amélioration d'une réponse immune contre l'antigène ou l'agent infectieux. L'invention concerne également des cellules immunes modifiées au moyen d'un conjugué, ces cellules étant utiles pour la génération ou l'amélioration d'une réponse immune contre un antigène ou un agent infectieux. L'invention concerne également des fractions immunostimulatoires comprenant un polypeptide co-stimulatoire immun, ces fractions étant utiles pour stimuler une réponse immune. L'invention concerne également des méthodes d'immunothérapie et des méthodes de traitement ou de prévention d'infections.
PCT/US2006/046662 2005-12-08 2006-12-07 Compositions et méthodes immunostimulatoires WO2007067681A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2006321888A AU2006321888A1 (en) 2005-12-08 2006-12-07 Immunostimulatory compositions and methods
JP2008544500A JP5564181B2 (ja) 2005-12-08 2006-12-07 免疫刺激組成物および方法
CA2632663A CA2632663C (fr) 2005-12-08 2006-12-07 Compositions et methodes immunostimulatoires
MX2008007292A MX2008007292A (es) 2005-12-08 2006-12-07 Composiciones inmunoestimuladoras y metodos.
EP06848503A EP1976565A2 (fr) 2005-12-08 2006-12-07 Compositions et méthodes immunostimulatoires

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US74817705P 2005-12-08 2005-12-08
US60/748,177 2005-12-08
US77117906P 2006-02-06 2006-02-06
US60/771,179 2006-02-06
US79964306P 2006-05-12 2006-05-12
US60/799,643 2006-05-12
US86317306P 2006-10-27 2006-10-27
US60/863,173 2006-10-27

Publications (2)

Publication Number Publication Date
WO2007067681A2 WO2007067681A2 (fr) 2007-06-14
WO2007067681A3 true WO2007067681A3 (fr) 2008-01-03

Family

ID=38123485

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/046662 WO2007067681A2 (fr) 2005-12-08 2006-12-07 Compositions et méthodes immunostimulatoires
PCT/US2006/046663 WO2007067682A2 (fr) 2005-12-08 2006-12-07 Modification in vivo de surfaces cellulaires

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2006/046663 WO2007067682A2 (fr) 2005-12-08 2006-12-07 Modification in vivo de surfaces cellulaires

Country Status (8)

Country Link
US (5) US7598345B2 (fr)
EP (2) EP1973572A2 (fr)
JP (2) JP2009518427A (fr)
KR (2) KR20080090411A (fr)
AU (2) AU2006321888A1 (fr)
CA (2) CA2632663C (fr)
MX (2) MX2008007292A (fr)
WO (2) WO2007067681A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US9005616B2 (en) 2009-08-31 2015-04-14 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
US9296822B2 (en) 2005-12-08 2016-03-29 E.R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
ATE531789T1 (de) 2000-06-30 2011-11-15 Univ Louisville Res Found Zellmembranenveränderung
EP3130350A1 (fr) 2005-06-08 2017-02-15 Dana-Farber Cancer Institute, Inc. Procédés et compositions pour le traitement du cancer et d'infections pérsistantes en inhibant la voie de la mort céllulaire programmée (pd-1)
WO2007067681A2 (fr) * 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Compositions et méthodes immunostimulatoires
AU2006321890A1 (en) * 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Methods and compositions for expanding T regulatory cells
JP5601836B2 (ja) * 2006-11-08 2014-10-08 マクロジェニックス ウエスト， インコーポレイテッド Ｔｅｓ７およびｔｅｓ７に結合する抗体
CN105056226A (zh) * 2006-12-27 2015-11-18 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
US8658180B2 (en) 2008-08-15 2014-02-25 Mark A. Miller Vaccines against influenza virus
DK2350129T3 (en) 2008-08-25 2015-08-31 Amplimmune Inc PREPARATIONS WITH PD-1 ANTAGONISTS AND PROCEDURES FOR USE THEREOF
KR20110074850A (ko) * 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
DK2370593T3 (en) * 2008-11-28 2016-07-04 Univ Emory A method for determining the effect of PD-1 Antagonists
SG10201708690SA (en) * 2008-12-09 2017-12-28 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
US8580274B2 (en) 2009-02-10 2013-11-12 University Of The Ryukyus Drug transporter, and adjuvant and vaccine each utilizing same
WO2010102278A1 (fr) * 2009-03-06 2010-09-10 President And Fellows Of Harvard College Procédés et compositions permettant de générer et de maintenir des cellules t de régulation
JP5550132B2 (ja) * 2009-10-30 2014-07-16 学校法人東京理科大学 抗原特異的ｂ細胞集団の製造方法
EP2335721A1 (fr) * 2009-12-21 2011-06-22 Institut Pasteur Système d'administration pour antigène contenant streptavidin et biotin
US8981057B2 (en) 2010-03-05 2015-03-17 Academisch Medisch Centrum Bij De Universiteit Van Amsterdam B-cell stimulating fusion proteins of an antigen with BAFF or APRIL
WO2012020842A1 (fr) * 2010-08-13 2012-02-16 独立行政法人理化学研究所 Complexe ayant un effet de vaccin antitumoral et son utilisation
US9233125B2 (en) * 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
CA2826582A1 (fr) * 2011-02-10 2012-08-16 University Of Louisville Research Foundation, Inc. Compositions d'adjuvant avec 4-1bbl
ES2864765T3 (es) 2011-05-11 2021-10-14 Childrens Medical Center Proteína de unión a biotina modificada, proteínas de fusión de la misma y aplicaciones
JP6120848B2 (ja) 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
HRP20230424T1 (hr) 2012-06-28 2023-07-07 University Of Central Florida Research Foundation Incorporated Postupci i pripravci za prirodnoubilačke stanice
WO2014076703A1 (fr) * 2012-11-14 2014-05-22 Silenseed Ltd. Procédés et compositions destinés au traitement du cancer
BR112015014063A2 (pt) 2012-12-19 2018-10-30 Amplimmune Inc anticorpos anti-b7-h4 humano e seus usos.
EP2951209A4 (fr) 2013-01-31 2016-06-22 Univ Jefferson Protéine de fusion agoniste des cd40 ox40 et ses utilisations
AU2014214844B2 (en) 2013-02-07 2017-12-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
WO2014145355A1 (fr) * 2013-03-15 2014-09-18 Stone Geoffrey W Composition composée d'un antigène lié à un ligand de la superfamille des tnf
AU2014337367B2 (en) 2013-10-15 2020-04-30 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
CN103966312B (zh) * 2014-03-19 2016-01-13 新乡学院 猪外周血单核淋巴细胞pd-l2重组质粒的构建、基因丰度实时检测方法及其应用
EP3148573A4 (fr) * 2014-05-29 2017-11-15 Medimmune, LLC Protéines de fusion ox40l et leurs utilisations
GB201410031D0 (en) * 2014-06-05 2014-07-16 Isis Innovation Polypeptides and uses thereof
WO2016154621A1 (fr) 2015-03-26 2016-09-29 The California Institute For Biomedical Research Récepteurs chimériques non-scfv commutables, commutateurs, et leurs utilisations
CN107708725A (zh) * 2015-04-02 2018-02-16 坎库雷有限公司 用于引发免疫应答的剂和组合物
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
DK3368068T3 (da) 2015-10-30 2021-02-22 Univ Copenhagen Viruslignende partikler med effektiv epitopdisplay
CN110267982B (zh) 2016-10-19 2024-02-23 斯克利普斯研究所 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途
EP3567049A4 (fr) * 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation Récepteur antigénique chimérique et cellules tueuses naturelles exprimant celui-ci
AU2018243910A1 (en) 2017-03-28 2019-11-14 The Children's Medical Center Corporation A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
AU2018289540A1 (en) 2017-06-23 2020-01-16 Verimmune Inc. Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
US11612647B2 (en) * 2017-06-23 2023-03-28 University Of Maryland, Baltimore Immunogenic compositions
US11779599B2 (en) 2017-11-07 2023-10-10 Coimmune, Inc. Methods and uses for dendritic cell therapy
WO2019173310A1 (fr) * 2018-03-05 2019-09-12 Oncoimmune, Inc. Méthodes d'utilisation de cd24 soluble pour le traitement du syndrome d'immunodéficience acquise (vih/sida)
EP3824097A4 (fr) * 2018-07-22 2022-03-30 Health Research, Inc. Vaccin à cellules cancéreuses exprimant le complexe majeur d'histocompatibilité de classe ii et procédés d'utilisation pour produire des réponses immunitaires intégrées
JP2021535921A (ja) 2018-09-12 2021-12-23 アフィニバックス、インコーポレイテッド 多価肺炎球菌ワクチン
WO2020102618A1 (fr) * 2018-11-15 2020-05-22 University Of Louisville Research Foundation, Inc. Monothérapie anticancéreuse utilisant la sa-4-1bbl
CA3125184A1 (fr) * 2018-12-27 2020-07-02 Verimmune Inc. Particules de type virus conjuguees et leurs utilisations en tant que redirecteurs immunitaires antitumoraux
IL293337A (en) * 2019-11-25 2022-07-01 Beyond Air Inc Nitrogen monoxide gas to treat tumors
JP2023552040A (ja) 2020-10-19 2023-12-14 ヴェリミューン インコーポレイテッド ウイルスにインスパイアされた組成物及びがんの治療のために同じものを使用して、既存の免疫応答をリダイレクトする方法
AU2021386358A1 (en) * 2020-11-30 2023-07-06 The University Of North Carolina At Chapel Hill Engineered cells functionalized with immune checkpoint molecules and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067788A2 (fr) * 1999-05-06 2000-11-16 Genetics Institute, Inc. Emploi de molecules de co-stimulation solubles favorisant les reponses immunitaires

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457035A (en) * 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6232088B1 (en) 1995-02-08 2001-05-15 Phairson Medical, Inc. Treatment and prevention of immune rejection reactions
US6312700B1 (en) * 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
ATE531789T1 (de) 2000-06-30 2011-11-15 Univ Louisville Res Found Zellmembranenveränderung
EP1736482A1 (fr) 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Ligand recombinant trimeric de 4-1BB
AU2006321890A1 (en) 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Methods and compositions for expanding T regulatory cells
WO2007067681A2 (fr) 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Compositions et méthodes immunostimulatoires

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067788A2 (fr) * 1999-05-06 2000-11-16 Genetics Institute, Inc. Emploi de molecules de co-stimulation solubles favorisant les reponses immunitaires

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ASAI T ET AL: "A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery", BIOMOLECULAR ENGINEERING, ELSEVIER, NEW YORK, NY, US, vol. 21, no. 6, February 2005 (2005-02-01), pages 145 - 155, XP004770257, ISSN: 1389-0344 *
ASKENASY NADIR ET AL: "Display of Fas ligand protein on cardiac vasculature as a novel means of regulating allograft rejection.", CIRCULATION, vol. 107, no. 11, 25 March 2003 (2003-03-25), pages 1525 - 1531, XP002449635, ISSN: 0009-7322 *
HUANG H-I: "Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 108, 2004, pages 696 - 703, XP002979404, ISSN: 0020-7136 *
HUANG T-H ET AL: "Enhanced antitumor immunity by fusion of CTLA-4 to a self tumor antigen", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 96, no. 12, 1 December 2000 (2000-12-01), pages 3663 - 3670, XP002955727, ISSN: 0006-4971 *
KILINC ET AL: "Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon", EXPERIMENTAL AND MOLECULAR PATHOLOGY, ACADEMIC PRESS, US, vol. 80, no. 3, June 2006 (2006-06-01), pages 252 - 261, XP005438933, ISSN: 0014-4800 *
KUDO-SAITO CHIE ET AL: "Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 FEB 2004, vol. 10, no. 3, 1 February 2004 (2004-02-01), pages 1090 - 1099, XP002449727, ISSN: 1078-0432 *
MORO MONICA ET AL: "Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 11, 1 June 1999 (1999-06-01), pages 2650 - 2656, XP002154490, ISSN: 0008-5472 *
ROHRBACH FLORIAN ET AL: "Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 MAY 2005, vol. 174, no. 9, 1 May 2005 (2005-05-01), pages 5481 - 5489, XP002454958, ISSN: 0022-1767 *
SINGH NARENDRA P ET AL: "A novel approach to cancer immunotherapy: Tumor cells decorated with CD80 generate effective antitumor immunity.", CANCER RESEARCH, vol. 63, no. 14, 15 July 2003 (2003-07-15), pages 4067 - 4073, XP002449633, ISSN: 0008-5472 *
SINGH NARENDRA P ET AL: "Primary tumor cells resected from cancer patients and decorated with a novel form of CD80 protein serve as effective antigen-presenting cells for the induction of autologous T cell immune responses ex vivo", HUMAN GENE THERAPY, vol. 17, no. 3, March 2006 (2006-03-01), pages 334 - 346, XP002449634, ISSN: 1043-0342 *
SINGH NARENDRA P ET AL: "ProtEx: a novel technology to display exogenous proteins on the cell surface for immunomodulation.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES NOV 2005, vol. 1056, November 2005 (2005-11-01), pages 344 - 358, XP009089115, ISSN: 0077-8923 *
YOLCU E S ET AL: "Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection", IMMUNITY, CELL PRESS, US, vol. 17, no. 6, 20 December 2002 (2002-12-20), pages 795 - 808, XP002231792, ISSN: 1074-7613 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296822B2 (en) 2005-12-08 2016-03-29 E.R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US9134321B2 (en) 2006-12-27 2015-09-15 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
US9005616B2 (en) 2009-08-31 2015-04-14 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
US9011853B2 (en) 2009-08-31 2015-04-21 Amplimmune, Inc. B7-H4 fusion proteins and methods of use thereof

Also Published As

Publication number Publication date
US20120171240A1 (en) 2012-07-05
US9079976B2 (en) 2015-07-14
MX2008007286A (es) 2008-10-21
EP1976565A2 (fr) 2008-10-08
US20070172504A1 (en) 2007-07-26
US7598345B2 (en) 2009-10-06
JP2009518426A (ja) 2009-05-07
US8017582B2 (en) 2011-09-13
AU2006321889A1 (en) 2007-06-14
WO2007067681A2 (fr) 2007-06-14
KR20080090412A (ko) 2008-10-08
CA2632682A1 (fr) 2007-06-14
JP5564181B2 (ja) 2014-07-30
EP1973572A2 (fr) 2008-10-01
KR20080090411A (ko) 2008-10-08
WO2007067682A3 (fr) 2007-11-15
US20100240585A1 (en) 2010-09-23
MX2008007292A (es) 2008-10-17
US20070184473A1 (en) 2007-08-09
CA2632663C (fr) 2015-08-18
US20100158936A1 (en) 2010-06-24
WO2007067682A2 (fr) 2007-06-14
JP2009518427A (ja) 2009-05-07
CA2632663A1 (fr) 2007-06-14
AU2006321888A1 (en) 2007-06-14

Similar Documents

Publication Publication Date Title
WO2007067681A3 (fr) Compositions et méthodes immunostimulatoires
EP1594536A4 (fr) Vaccin contre la grippe contenant un adjuvant
WO2004032829A3 (fr) Compositions immunostimulantes et procedes de stimulation d'une reponse immune
TR200102739T2 (tr) Aşı
WO2006082406A3 (fr) Proteines et anticorps humains
WO2006071983A3 (fr) Combinaisons d'antigenes associes a une tumeur dans des compositions pour differents types de cancers
IL214325A (en) Antibody against cmet, a drug that includes and uses it
WO2006081007A3 (fr) Utilisation de flagelline en immunotherapie antitumorale
HK1135431A1 (en) Therapeutic applications of activation of human antigen-presenting cells through dectin-1
MX2007002787A (es) Adyuvante de glicosilceramida para antigenos de sacarido.
WO2008103947A3 (fr) Activation de cellules humaines présentant un antigène par l'intermédiaire de clec-6
TW200732349A (en) Anti-OX40L antibodies and methods using same
WO2006113214A3 (fr) Vaccin contre des souches pandemiques des virus de la grippe
WO2004030608A3 (fr) Vaccins sous forme de nanoemulsion
WO2006066003A3 (fr) Methodes et compositions permettant d'induire ou de stimuler la tolerance immunitaire
MY154956A (en) Chimeric adenoviral vectors
WO2006047515A3 (fr) Cellules dendritiques chargees de corps cellulaires de melanome de choc thermique
WO2006126981A3 (fr) Compositions et methodes destinees a la vaccination par voie muqueuse
WO2004112825A3 (fr) Combinaisons d'antigenes associes a des tumeurs dans des compositions pour divers types de cancers
WO2005070959A3 (fr) Compositions renfermant des agents de modification de reponse immunitaire et procedes d'utilisation
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2004083404A3 (fr) Vecteurs de therapie genique presentant une antigenicite reduite
WO2007150008A3 (fr) Polypeptides issus du virus de la peste porcine africaine utilisés en tant que vaccins à usage préventif et thérapeutique
WO2005007673A3 (fr) Peptides immunogenes
WO2007016715A3 (fr) Preparations induisant une reponse immunitaire

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/007292

Country of ref document: MX

Ref document number: 2008544500

Country of ref document: JP

Ref document number: 2006321888

Country of ref document: AU

Ref document number: 2632663

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 568982

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006321888

Country of ref document: AU

Date of ref document: 20061207

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2006848503

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 5924/DELNP/2008

Country of ref document: IN

Ref document number: 1020087016530

Country of ref document: KR

Ref document number: 2006848503

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008127465

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200680052551.6

Country of ref document: CN